Impact of hepatoprotective medications on the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir plus /- ribavirin in hepatitis C virus genotype 1b-infected Asian patients with and without cirrhosis in the ONYX-I and -II studies

被引：0

作者：

Chuang, W. -L. ^{[1
]}

Luo, Y. ^{[2
]}

Heo, J. ^{[3
,4
]}

Wang, G. -Q. ^{[5
]}

Yu, M. -L. ^{[6
,7
]}

Kim, Y. J. ^{[8
,9
]}

Xie, Q. ^{[10
]}

Peng, C. -Y. ^{[11
]}

Zhang, M. ^{[12
]}

Huang, Y. ^{[13
]}

Lu, W. ^{[2
]}

Fredrick, L. M. ^{[2
]}

Mobashery, N. ^{[2
]}

Wei, L. ^{[14
]}

机构：

[1] Kaohsiung Med Univ, Kaohsiung, Taiwan

[2] AbbVie Inc, N Chicago, IL USA

[3] Pusan Natl Univ, Dept Internal Med, Busan, South Korea

[4] Pusan Natl Univ Hosp, Med Res Inst, Busan, South Korea

[5] Peking Univ, Hosp 1, Beijing, Peoples R China

[6] Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan

[7] Kaohsiung Med Univ Hosp, Hepatitis Ctr, Kaohsiung, Taiwan

[8] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[9] Seoul Natl Univ, Coll Med, Liver Res Inst, Seoul, South Korea

[10] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai, Peoples R China

[11] China Med Univ Hosp, Taichung, Taiwan

[12] Sixth Peoples Hosp Shenyang, Shenyang, Peoples R China

[13] Cent S Univ, Xiangya Hospita, Dept Infect Dis, Changsha, Hunan, Peoples R China

[14] Peking Univ, Peoples Hosp, Beijing, Peoples R China

来源：

关键词：

D O I：

10.1016/S0168-8278(17)31985-2

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT-291

引用

页码：S746 / S746

页数：1